Amplification of antibody production by phosphorothioate oligodeoxynucleotides

Journal of Laboratory and Clinical Medicine

Volumn 128, Issue 3, 1996, Pages 329-338

  Branda, Richard F ^a   Moore, Ann L ^b   Lafayette, Amy R ^b   Mathews, Linda ^b   Hong, Richard ^b   Zon, Gerald ^b   Brown, Thomas ^b   Mccormack, John J ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030231262     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90035-9     Document Type: Article

References (30)

1. Cohen JS. Oligonucleotides as therapeutic agents. Pharmacol Ther 1991;52:211-25.
2. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994;372:333-5.
3. Fakler B, Herlitze S, Amthor B, Zenner H-P, Ruppersberg H-P. Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J Biol Chem 1994;269:16187-94.
4. Ma DDF, Doan TL. Antisense oligonucleotide therapies: are they the "magic bullets". Ann Intern Med 1994;120:161-3.
5. Kirkland MA, O'Brien SG, Goldman JM. Antisense therapeutics in haematological malignancies. Br J Haematol 1994; 87:447-52.
6. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science 1993;261: 1004-12.
7. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G. Immune stimulation by an antisense oligomer which is complementary to the rev gene of HIV-1. Biochem Pharmacol 1993;45:2037-43.
8. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G. Stimulation of peripheral blood mononuclear cells (PBMNCs) from chronic lymphatic leukemia (CLL) patients by an antisense phosphorothioate oligomer to the rev gene of HIV [abstract]. Proceedings of the American Association for Cancer Research 1993;34:455.
9. Branda RF, Moore AL, Hong R, McCormack JJ, Zon G, Cunningham-Rundles C. B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol 1996;79:115-21.
10. Ershler WB, Moore AL, Hacker MP. Specific in vivo and in vitro antibody response to tetanus toxoid immunization. Clin Exp Immunol 1982;49:552-8.
11. Winer BJ. Statistical principles in experimental design. New York: McGraw-Hill, 1971:296-301.
12. Krieg AM, Yi A-Y, Matson S, et al. CpG motifs in baterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
13. Harel-Bellan A, Ferris DK, Vinocouir M, Holt JT, Farrar WL. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol 1988;140:2431-5.
14. Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, Griffin JD. cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science 1990;250:805-8.
15. Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B. G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science 1989;245:180-3.
16. 1 phase. Scand J Immunol 1994;39:499-504.
17. Tanaka T, Chu CC, Paul WE. An antisense oligonucleotide complementary to a sequence in Iγ2b increases γ2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. J Exp Med 1992;175:597-607.
18. Mojcik CF, Gourley MF, Klinman DM, Krieg AM, Gmelig-Meyling F, Steinberg AD. Administration of a phosporothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin Immunol Immunopathol 1993;67:130-6.
19. Krieg AM, Gause WC, Gourley MF, Steinberg AD. A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol 1989;143:2448-51.
20. McIntyre KW, Lombard-Gillooly K, Perez JR, et al. A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kB p65 causes sequence-specific immune stimulation. Antisense Res Dev 1993;3:309-22.
21. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 1996;51: 173-82.
22. Burgess TL, Fisher EF, Ross SL, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995;92:4051-5.
23. Yaswen P, Stampfer MR, Ghosh K, Cohen JS. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 1993;3:67-77.
24. Maltese J-Y, Sharma HW, Vassilev L, Narayanan R. Sequence context of antisense RelA/NF-kB phosphorothioates determines specificity. Nucleic Acids Res 1995;23:1146-51.
25. Baeuerle PA. The inducible transcription activator NF-kB: regulation by distinct protein subunits. Biochim Biophys Acta 1991;1072:63-80.
26. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol 1994;12:141-79.
27. Pisetsky DS, Reich CF. Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci 1994;54: 101-7.
28. Spinolo J, Bayever E, Iversen P, et al. Toxicity of human p53 antisense oligonucleotide infusions in Rhesus macacca. Proceedings of the American Association for Cancer Research 1992;33:523.
29. Iversen P, Cornish K, Johansson S, et al. Systemic human p53 antisense oligonucleotide in Rhesus monkey. Proceedings of the American Association for Cancer Research 1992;33:522.
30. Bishop MR, Bayever E, Iversen PL, et al. Phase I trial of systemic administration of ol(1)p53 oligonucleotide in refractory acute myelogenous leukemia and advanced myeloysplastic syndrome [abstract]. Blood 1993;82(suppl 1):443a.